PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

Epithelial Ovarian Cancer Clinical Trial

Official title:

A Multicenter, Open-Label, Parallel, Phase 2a Study of PLX2853 Monotherapy in Advanced Gynecological Malignancies With a Known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04493619
• Other study ID #: PLX124-03
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: August 11, 2020
• Est. completion date: April 25, 2022

Study information

• Verified date: October 2022
• Source: Opna-IO LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in Advanced Gynecological Malignancies with a Known ARID1A Mutation and PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 37
• Est. completion date: April 25, 2022
• Est. primary completion date: April 25, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age =18 years at the time of signing informed consent

2. Histologically or cytologically confirmed diagnosis of 1 of the following, and must

have measurable disease per RECIST v1.1:

• Phase 2a (PLX2853 monotherapy): Any advanced gynecological malignancy (cervical, vaginal, vulvar, uterine, ovarian, fallopian tube, or primary peritoneal) with a known ARID1A mutation, that is intolerant to or refractory to all standard therapy known to confer clinical benefit.
• Phase 1b and Phase 2a (PLX2853 + carboplatin combination):

Platinum-resistant EOC (including fallopian tube or primary peritoneal cancer).

3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1

4. Adequate organ function as demonstrated by laboratory values.

5. Women of child bearing potential (defined as any female who has experienced menarche and who has not undergone successful surgical sterilization or is not postmenopausal) must have a negative serum pregnancy test within 7 days prior to taking the first dose of study drug and, if sexually active, must agree to use a highly effective method of contraception (a contraception method with a failure rate <1% per year) and 1 additional barrier method from the time of the negative pregnancy test to 90 days after the last dose of study drug. Women of non-child bearing potential may be included if they are either surgically sterile or have been postmenopausal for =1 year.

6. Except as specified above for organ function, all drug-related toxicity from previous cancer therapy must be resolved (to Grade =1 or baseline per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 [NCI CTCAE v5.0]) prior to study treatment administration (Grade 2: alopecia, hot flashes, decreased libido, or neuropathy is allowed).

7. Willingness and ability to provide written informed consent prior to any study-related procedures and to comply with all study requirements

Exclusion Criteria:

1. Prior exposure to a bromodomain inhibitor

2. Ongoing systemic infection requiring treatment with antibiotic, antiviral, or antifungal treatment

3. Autoimmune hemolytic anemia or autoimmune thrombocytopenia

4. Presence of symptomatic or uncontrolled central nervous system or leptomeningeal metastases

5. Red blood cell or platelet transfusion within 14 days of Screening blood draw

6. Known or suspected allergy to the investigational agent or any agent given in association with this study

7. Use of biotin (i.e., Vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 µg (NIH-ODS 2020).

8. Use of strong inhibitors and inducers of CYP3A4 and 2C8

9. Clinically significant cardiac disease

10. Inability to take oral medication or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the Investigator, would preclude adequate absorption

11. Non-healing wound, ulcer, or bone fracture

12. Infection with HIV-1 or HIV-2. Exception: subjects with well-controlled HIV (e.g., CD4 >350/mm3 and undetectable viral load) are eligible.

13. Current active liver disease from any cause, including hepatitis A (hepatitis A virus immunoglobulin M positive), hepatitis B (hepatitis B virus [HBV] surface antigen positive), or hepatitis C (hepatitis C virus [HCV] antibody positive, confirmed by HCV ribonucleic acid).

14. Active known second malignancy with the exception of any of the following:

• Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer
• Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for =2 years
• Any other cancer from which the subject has been disease-free for =3 years

15. Major surgery or significant traumatic injury within 28 days prior to Cycle 1 Day 1

16. Hospitalization for subacute bowel obstruction within 28 days prior to Cycle 1 Day 1

17. Receipt of anti-cancer therapy prior to Cycle 1 Day 1:

• Chemotherapy, radiation therapy, or small molecule anti-cancer therapy for the treatment of cancer within 14 days or 5 half-lives (whichever is shorter) of Cycle 1 Day 1
• Immune therapy or other biologic therapy (e.g., monoclonal antibodies, antibody-drug conjugates) for the treatment of cancer within 21 days or 5 half-lives (whichever is shorter) of Cycle 1 Day 1 Subjects can receive a stable dose of bisphosphonates for bone metastases, before and during the study as long as these were started at least 28 days prior to treatment with study drug.

18. Subject is participating in any other therapeutic clinical study (observational or registry studies are allowed).

19. Subjects who are pregnant or breast-feeding

20. Presence of any other medical, psychological, familial, sociological, or geographic condition potentially hampering compliance with the study protocol or would interfere with the study endpoints or the subject's ability to participate.

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Epithelial Ovarian Cancer
• Genital Neoplasms, Female
• Gynecologic Neoplasms
• Neoplasms
• Ovarian Neoplasms

Intervention

Drug:
• PLX2853
PLX2853 tablets
• Carboplatin
Carboplatin IV injection, 5 mg•min/mL

Locations

Country	Name	City	State
Canada	Princess Margaret Cancer Centre	Toronto	Ontario
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	University of Virginia Health Systems	Charlottesville	Virginia
United States	The University of Chicago Medical Center	Chicago	Illinois
United States	Virginia Cancer Specialists, PC	Fairfax	Virginia
United States	Tennessee Oncology / Sarah Cannon	Nashville	Tennessee
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	University of Oklahoma - Stephenson Cancer Center	Oklahoma City	Oklahoma
United States	University of Washington / Seattle Cancer Care Alliance	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Opna-IO LLC

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 2a (PLX2853 monotherapy): overall response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)		From 8 weeks of treatment for only PLX2853 (Cycle 3 Day 1; 28 days per cycle) until completion of long term follow-up, an average of 6 months.
Primary	Phase 1b (PLX2853 + carboplatin combination): establish the MTD/RP2D for the combination of PLX2853 and carboplatin		From time of first dose of PLX2853 and Carboplatin until 30 days of end of treatment.
Primary	Phase 2a (PLX2853 + carboplatin combination): ORR as measured by RECIST v1.1		From 8 weeks of treatment with PLX2853 and Carboplatin (Cycle 3 Day 1; 28 days per cycle) until completion of long term follow-up, an average of 6 months.
Secondary	Incidence of TEAEs that are related to treatment (both arms)		From time of first dose of PLX2853 and Carboplatin until 30 days of end of treatment.
Secondary	Incidence of TEAEs that result in dose interruption, reduction or discontinuation (both arms)		From time of first dose of PLX2853 and Carboplatin until 30 days of end of treatment.
Secondary	Incidence of treatment-emergent ECG abnormalities (both arms)		From time of first dose of PLX2853 and Carboplatin until 30 days of end of treatment.
Secondary	Incidence of treatment-emergent laboratory abnormalities (both arms)		From time of first dose of PLX2853 and Carboplatin until 30 days of end of treatment.
Secondary	Duration Of Response (DOR) (both arms)	DOR will be calculated for each subject with a response as the number of days from the date of first response (PR or CR confirmed at least 28 days later) to the date of the first documented disease progression or date of death from any cause, whichever occurs first.	From 8 weeks of treatment (Cycle 3 Day 1; 28 days per cycle) until completion of long term follow-up, an average of 6 months.
Secondary	Disease control rate (DCR) (both arms)	DCR will be calculated as the percentage of subjects with confirmed complete response (CR), Partial Response (PR), or Stable Disease (SD).	From time of first dose until end of treatment, an average of 6 months.
Secondary	Progression-free survival (PFS) (both arms)	Progression-free survival (PFS) will be calculated for each subject as the number of days from the first day of PLX2853 treatment (Cycle 1 Day 1) to the date of the first documented disease progression or date of death from any cause, whichever occurs first.	From time of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 24 months.
Secondary	Overall survival (OS) (both arms)	Overall survival (OS) will be calculated for each subject as the number of days from the first day of PLX2853 treatment (Cycle 1 Day 1) to the date of death from any cause.	From time of first dose until completion of long term follow-up, approximately 24 months.
Secondary	PLX2853 PK parameter AUC0-last (both arms)	AUC from time zero to time of last observed concentration hours postdose (AUC0-last).	From time of first dose until 30 days from end of treatment.
Secondary	PLX2853 PK parameter AUC0-24 (both arms)	AUC from time zero extrapolated to 24 hours (AUC0-24)	From time of first dose until 30 days from end of treatment.
Secondary	PLX2853 PK parameter AUC0-8 (both arms)	AUC from time zero extrapolated to infinite time (AUC0-8)	From time of first dose until 30 days from end of treatment.
Secondary	PLX2853 PK parameter Cmax (both arms)	Maximum observed concentration	From time of first dose until 30 days from end of treatment.
Secondary	PLX2853 PK parameter Tmax (both arms)	Time to maximum observed concentration	From time of first dose until 30 days from end of treatment.
Secondary	PLX2853 PK parameter T1/2 (both arms)	terminal elimination half-life (T1/2)	From time of first dose until 30 days from end of treatment.
Secondary	PLX2853 PK parameter accumulation ratio at steady state (both arms)	accumulation ratio at steady state	From time of first dose until 30 days from end of treatment.